Sponsor survey: Covance, Quintiles, PPD to dominate the CRO space

By Dan Stanton contact

- Last updated on GMT

Over 160 sponsors responded to a survey to offer insight into the CRO industry
Over 160 sponsors responded to a survey to offer insight into the CRO industry

Related tags: Contract research organization

Covance, Quintiles and PPD are expected to lead the CRO space going forward according to a sponsor survey from the Life Science Strategy Group.

In August, research company Life Science Strategy Group (LSSG) surveyed 161 study participants, consisting of a mixture of executives from Big Pharma, mid-tier sponsors and emerging biotechs – the majority from North America - in order to identify current and future trends in the contract research organisation (CRO) sector.

We still see patient recruitment, study start-up, and on-time delivery as performance factors influencing perceptions of leadership today,”​ Jon Meyer, LSSG’s CRO Industry Practice Leader, told Outsourcing-Pharma.com.

We are seeing increased importance being placed on data accuracy and communication, among other areas.  The report also explores satisfaction with different trial conduct activities and identifies key gaps between CRO service delivery and customer expectations.”

The results also found sponsors scored Quintiles, PPD and Covance high on their technology and informatics strength, and that these CROs are “most likely to be future leaders in the category.”

Nearly a quarter of respondents expected Covance to have a much bigger leadership presence in the space over the next 3 years, due - the report speculates – to the growth of its clinical business and perceived benefits from its acquisition by Labcorp​.

Quintiles, meanwhile, was cited by 17% of respondents as future leaders. “This is likely a reflection of its global scale and breadth of therapeutic expertise,”​ the report said. PPD came in third with 14%.

Top of the charts

The survey forms part of LSSG’s Pharma Outsourcing focus which last year saw the creation of a ‘Yelp-like’ website​ to allow sponsors to rate and offer insight into CRO partners.

In this report, Covance and Quintiles also topped the poll in terms of which CROs sponsors said they would definitely work with over the coming years, due to their “size, capabilities and expertise,”​ the report said.

At the other end of the spectrum, 16% of respondents said they will definitely not work with InVentiv, while 11% said they would not work with PRA, Parexel and - interestingly - Quintiles and Covance.

“LSSG believes respondents will not work with InVentiv Health Clinical due in part to the low – comparatively - performance scores in this study, but also because it is a smaller clinical player.”

But Covance, Quintiles and PPD should not get too complacent, as they were also picked out as the CROs most in need of major changes over the next 1-3 years for sponsors to consider working with them, which the report said may be due to poor past performance in terms of timelines and/or cost, “and perceived lack of attention/focus given to small/mid pharma by large CROs.”

Related news

Show more

Related products

show more

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars